Genmab A (GMAB) Interest & Investment Income (2019 - 2026)
Genmab A (GMAB) reported Interest & Investment Income of $44.0 million for Q1 2026, down 56.44% on a YoY basis from $101.0 million in Q1 2025, and down 85.9% quarter-over-quarter from $312.0 million in Q3 2025.
Genmab A (GMAB) Interest & Investment Income (2019 - 2026) Analysis & Trends
Genmab A has reported Interest & Investment Income for 6 years, with the latest figure at $44.0 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 56.44% year-over-year to $44.0 million; the trailing twelve-month figure through Mar 2026 stood at $44.0 million (down 56.44% YoY), and the FY2025 full-year result was $408.0 million, up 163.26% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $44.0 million, down from $312.0 million in the prior quarter.
- The five-year high for Interest & Investment Income was $328.0 million in Q3 2024, with the low at -$645.0 million in Q4 2024.
- Historically, Interest & Investment Income has averaged -$58.7 million across 4 years, with a median of $44.0 million in 2026.
- Annual changes were most pronounced in 2024 — Interest & Investment Income plunged 115.72% — and 2025, when it advanced 10.92%.
- Genmab A's Interest & Investment Income stood at -$299.0 million in 2023, then plunged by 115.72% to -$645.0 million in 2024, then soared by 148.37% to $312.0 million in 2025, then plunged by 85.9% to $44.0 million in 2026.
- The last three Interest & Investment Income figures came in at $44.0 million (Q1 2026), $312.0 million (Q3 2025), and -$253.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 597,319.59 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -14.79 Mn |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | 44.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.00 Mn |
| Sep 30, 2025 | 312.00 Mn |
| Jun 30, 2025 | -253.00 Mn |
| Mar 31, 2025 | 101.00 Mn |
| Dec 31, 2024 | -645.00 Mn |
| Sep 30, 2024 | 328.00 Mn |
| Jun 30, 2024 | -284.00 Mn |
| Mar 31, 2024 | 168.00 Mn |
| Dec 31, 2023 | -299.00 Mn |
| Sep 30, 2020 | 616.00 |
| Dec 31, 2019 | 356.00 |
| Sep 30, 2019 | 448.00 |